Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2019 June;71(3) > Minerva Ginecologica 2019 June;71(3):191-5

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

ORIGINAL ARTICLE   Freefree

Minerva Ginecologica 2019 June;71(3):191-5

DOI: 10.23736/S0026-4784.19.04384-3

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Role of a natural integrator based on lipoic acid, palmitoiletanolamide and myrrh in the treatment of chronic pelvic pain and endometriosis

Vincenzo DE LEO 1 , Angelo CAGNACCI 2, Valentina CAPPELLI 1, Anna BIASIOLI 2, Deborah LEONARDI 3, Renato SERACCHIOLI 3

1 Unit of Obstetrics and Gynecology, Department of Molecular Medicine and Development, Università degli Studi, Siena, Italy; 2 Unit of Obstetrics and Gynecology, Azienda Sanitaria Universitaria Integrata di Udine, Udine, Italy; 3 Unit of Gynecology and Human Reproduction Physiopathology, Department of Obstetrics and Gynecology, S. Orsola Hospital, University of Bologna, Bologna, Italy



BACKGROUND: Dysmenorrhea and chronic pelvic pain occur in a significantly higher percentage in women with endometriosis; this benign condition has an incidence ranging from 5% to 10% in the general population, while 35% to 50% of infertile women are affected. Treatment of the symptoms demands integrated approaches with the use of anti-inflammatory substances or drugs and lifestyle changes, including attention to diet. The use of traditional anti-inflammatory drugs over the long term is not very successful because of the fear of side effects so they are almost always used with a short-term formula of 7-10 days when the woman’s general condition becomes difficult to bear. In recent years, particular attention has been paid to natural substances with recognized anti-inflammatory activities that, associated with one another, are able to synergize individual actions. A nutraceutical containing substances capable of fighting chronic pelvic pain has recently been put on the market. The possible action mechanism derives from a synergy of action between alpha-lipoic acid, palmitoiletanolamide (PEA) and myrrh (Pelvinox, Laborest Italia srl, Nerviano, Milan, Italy), whose action is so effective that it is able to replace the use of anti-inflammatory drugs. The aim of the study was to evaluate the effect of these active ingredients in women with endometriosis and chronic pelvic pain.
METHODS: This multicenter study saw the recruitment of 60 women (divided between the three centers participating in the study, Siena, Bologna and Udine) aged between 20 and 39 suffering from endometriosis (ovarian) and chronic pelvic pain. All the women took one nutraceutical (Pelvinox) at a dose of two tablets per day for 6 months.
RESULTS: The results showed a significant reduction in pain symptoms as regards dyspareunia, dysmenorrhea and chronic pelvic pain, while there was no change in the mean diameter of the endometriosis cysts.
CONCLUSIONS: In light of the above, it is believed that substances such as alpha-lipoic acid, PEA and myrrh may play a very important role in this type of patient in the treatment of individual symptoms.


KEY WORDS: Endometriosis; Dysmenorrhea; Pain

top of page